436 related articles for article (PubMed ID: 15739020)
21. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
23. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
Pirinen R; Lipponen P; Syrjänen K
Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
[TBL] [Abstract][Full Text] [Related]
24. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
Keshgegian AA
Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
[TBL] [Abstract][Full Text] [Related]
25. Progesterone and estrogen receptors as prognostic variables in breast cancer.
Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG
Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609
[TBL] [Abstract][Full Text] [Related]
26. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
29. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
30. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
[TBL] [Abstract][Full Text] [Related]
32. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
[TBL] [Abstract][Full Text] [Related]
33. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
Blanco G; Alavaikko M; Ojala A; Collan Y; Heikkinen M; Hietanen T; Aine R; Taskinen PJ
Anticancer Res; 1984; 4(6):383-9. PubMed ID: 6097159
[TBL] [Abstract][Full Text] [Related]
34. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
35. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
Scorilas A; Diamandis EP; Levesque MA; Papanastasiou-Diamandi A; Khosravi MJ; Giai M; Ponzone R; Roagna R; Sismondi P; López-Otin C
Clin Cancer Res; 1999 Jul; 5(7):1778-85. PubMed ID: 10430082
[TBL] [Abstract][Full Text] [Related]
36. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
37. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients.
Alo' PL; Visca P; Marci A; Mangoni A; Botti C; Di Tondo U
Cancer; 1996 Feb; 77(3):474-82. PubMed ID: 8630954
[TBL] [Abstract][Full Text] [Related]
38. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
39. [Demonstration of the effect of estrogen and progesterone receptors on survival in breast cancer without cytostatic and hormonal treatment in a small set of patients].
Hochmann J
Klin Onkol; 2010; 23(1):25-33. PubMed ID: 20192071
[TBL] [Abstract][Full Text] [Related]
40. The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients.
Crowe JP; Gordon NH; Hubay CA; Pearson OH; Marshall JS; McGuire WL
Surgery; 1986 Oct; 100(4):599-605. PubMed ID: 3764686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
